F. Hoffmann La Roche, Innovation Center Basel, Hoffmann La Roche, Basel, 4070, Switzerland.
Institute of Psychiatry, Psychology & Neuroscience, King's College London, Camberwell, London, SE5 8AF, UK.
Autism Res. 2018 Feb;11(2):270-283. doi: 10.1002/aur.1874. Epub 2017 Sep 21.
Autism Spectrum Disorder (ASD) is associated with persistent impairments in adaptive abilities across multiple domains. These social, personal, and communicative impairments become increasingly pronounced with development, and are present regardless of IQ. The Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) is the most commonly used instrument for quantifying these impairments, but minimal clinically important differences (MCIDs) on Vineland-II scores have not been rigorously established in ASD. We pooled data from several consortia/registries (EU-AIMS LEAP study, ABIDE-I, ABIDE-II, INFOR, Simons Simplex Collection and Autism Treatment Network [ATN]) and clinical investigations and trials (Stanford, Yale, Roche) resulting in a data set of over 9,000 individuals with ASD. Two approaches were used to estimate MCIDs: distribution-based methods and anchor-based methods. Distribution-based MCID [d-MCID] estimates included the standard error of the measurement, as well as one-fifth and one-half of the covariate-adjusted standard deviation (both cross-sectionally and longitudinally). Anchor-based MCID [a-MCID] estimates include the slope of linear regression of clinician ratings of severity on the Vineland-II score, the slope of linear regression of clinician ratings of longitudinal improvement category on Vineland-II change, the Vineland-II change score maximally differentiating clinical impressions of minimal versus no improvement, and equipercentile equating. Across strata, the Vineland-II Adaptive Behavior Composite standardized score MCID estimates range from 2.01 to 3.2 for distribution-based methods, and from 2.42 to 3.75 for sample-size-weighted anchor-based methods. Lower Vineland-II standardized score MCID estimates were observed for younger and more cognitively impaired populations. These MCID estimates enable users of Vineland-II to assess both the statistical and clinical significance of any observed change. Autism Res 2018, 11: 270-283. © 2017 International Society for Autism Research, Wiley Periodicals, Inc.
The Vineland Adaptive Behavior Scales (2nd edition; Vineland-II) is the most widely used scale for assessing day-to-day "adaptive" skills. Yet, it is unknown how much Vineland-II scores must change for those changes to be regarded as clinically significant. We pooled data from over 9,000 individuals with ASD to show that changes of 2-3.75 points on the Vineland-II Composite score represent the "minimal clinically-important difference." These estimates will help evaluate the benefits of potential new treatments for ASD.
自闭症谱系障碍(ASD)与多个领域的适应性能力持续受损有关。这些社交、个人和沟通方面的障碍随着发育的发展变得越来越明显,无论智商如何,这些障碍都存在。维兰纳适应行为量表第二版(Vineland-II)是用于量化这些障碍的最常用工具,但在 ASD 中尚未严格确定 Vineland-II 评分的最小临床重要差异(MCID)。我们从几个联盟/注册处(EU-AIMS LEAP 研究、ABIDE-I、ABIDE-II、INFOR、Simons Simplex 集合和自闭症治疗网络[ATN])和临床研究和试验(斯坦福大学、耶鲁大学、罗氏)中汇集数据,得到了一个超过 9000 名 ASD 个体的数据集。使用了两种方法来估计 MCID:基于分布的方法和基于锚的方法。基于分布的 MCID[d-MCID]估计值包括测量的标准误差,以及协变量调整后的标准偏差的五分之一和一半(横截面和纵向)。基于锚的 MCID[a-MCID]估计值包括临床医生对 Vineland-II 评分严重程度的线性回归斜率、临床医生对纵向改善类别的线性回归斜率、最大区分临床印象最小与无改善的 Vineland-II 变化评分以及等百分位配准。在各层中,基于分布的方法的 Vineland-II 适应性行为综合标准评分 MCID 估计值范围为 2.01 至 3.2,样本大小加权锚定方法的 MCID 估计值范围为 2.42 至 3.75。对于年龄较小和认知障碍较重的人群,Vineland-II 标准化评分的 MCID 估计值较低。这些 MCID 估计值使 Vineland-II 的用户能够评估任何观察到的变化的统计和临床意义。自闭症研究 2018,11:270-283。©2017 自闭症国际研究协会,威利期刊,公司。
维兰纳适应行为量表(第二版;Vineland-II)是评估日常“适应性”技能的最广泛使用的量表。然而,尚不清楚 Vineland-II 评分必须改变多少才能被视为具有临床意义。我们从超过 9000 名 ASD 个体的数据中汇总数据,表明 Vineland-II 综合评分的 2-3.75 分变化代表“最小临床重要差异”。这些估计值将有助于评估潜在新 ASD 治疗方法的益处。